Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma
Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma
复制标题
DOI：
10.1309/x6nxye57dlue2nq8
复制
发表时间：
2007-04-01
影响因子：
3.5
通讯作者：
Saad, Reda S.
中科院分区：
文献类型：
--
作者：
El-Gohary, Yasser M.;Silverman, Jan F.;Saad, Reda S.
我们研究了50例前列腺癌根治术标本中内皮素和血管内皮生长因子（VEGF）的表达作为预后标志物。根据Gleason评分进一步分类如下：8 - 10分9例; 7（4 + 3）分9例; 7（3 + 4）分14例; 6分13例; 4或5分5例。所有病例均进行内皮素、CD 31和VEGF免疫染色。在x 400视野中，对密集血管灶中的阳性染色微血管进行计数。VEGF染色强度以2级量表评分。结果与生存率和其他参数相关。内皮糖蛋白比CD 31显示出显著更多的微血管（平均值+/- SD，37 +/- 15 vs 22 +/- 17; P < .001）。VEGF低表达21例（42%），高表达29例（58%）。Endoglin与Gleason评分、淋巴结转移、肿瘤分期和术前前列腺特异性抗原水平呈正相关（P <0.05），但与CD 31无关。VEGF与血管淋巴管浸润和Gleason评分显著相关（P <0.05）。高内皮素微血管计数和VEGF表达与较短的生存期相关。Endoglin是一种比CD 31更特异和敏感的肿瘤血管生成标志物，可作为前列腺癌的预后标志物。
We studied endoglin and vascular endothelial growth factor (VEGF) expression as prognostic markers in prostatic adenocarcinoma in 50 radical prostatectomy specimens. Cases were further categorized by Gleason score as follows: 8 to 10, 9 cases; 7 (4 + 3), 9 cases; 7 (3 + 4), 14 cases; 6, 13 cases; and 4 or 5, 5 cases. All cases were immunostained for endoglin, CD31, and VEGF Positively stained microvessels were counted in densely vascular foci in a x 400 field. VEGF staining intensity was scored on a 2-tiered scale. Results were correlated with survival and other parameters. Endoglin demonstrated significantly more microvessels than did CD31 (mean +/- SD, 37 +/- 15 vs 22 +/- 17; P < .001). VEGF expression was low in 21 cases (42%) and high in 29 (58%). Endoglin correlated positively with Gleason score, lymph node metastases, tumor stage, and preoperative prostate-specific antigen level (P < .05) but not with CD31. VEGF correlated significantly with angiolymphatic invasion and Gleason score (P < .05). A high endoglin microvessel count and VEGF expression correlated with shorter survival. Endoglin is a more specific and sensitive marker for tumor angiogenesis than CD31 and may serve as a prognostic marker for prostatic adenocarcinoma.